Kyntra Bio (KYNB) Asset Writedowns and Impairment (2023)

Kyntra Bio has reported Asset Writedowns and Impairment for 1 years, with the latest figure at $1.0 million in Q1 2023.

• Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $1.0 million in Q1 2023, while the trailing twelve-month figure through Dec 2023 was $1.0 million (changed N/A YoY) and the FY2025 annual result came in at $2.1 million, changed N/A from the prior year.
• Asset Writedowns and Impairment held at $1.0 million in Q1 2023 per KYNB's latest filing.
• Over five years, Asset Writedowns and Impairment peaked at $1.0 million in Q1 2023 and troughed at $1.0 million in Q1 2023.